Melinda Soeung, Xinmiao Yan, Ciro Zanca, Jing Qian, Menuka Karki, Fei Duan, Hania Khan, Li Zhang, David H. Peng, Mariah Williams, Rong He, Ziheng Chen, Luigi Perelli, Jianfeng Chen, Rebecca S. Tidwell, Pankaj K. Chauhan, Courtney N. Le, Truong N. A. Lam, Nirjar Bhattacharya, Rutvi Shah, I-Lin Ho, Jason P. Gay, Caroline C. Carrillo, Ningping Feng, Kang Le, Guang Gao, Teresa L. Perry, Faika Mseeh, Yongying Jiang, Quanyun A. Xu, Niki Marie Zacharias, Rahul A. Sheth, Tharakeswara K. Bathala, Priya Rao, Najat C. Daw, Durga N. Tripathi, Cheryl L. Walker, Mohammad M. Mohammad, Jianhua Zhang, Guangchun Han, Yanshuo Chu, Ruiping Wang, Minghao Dang, Enyu Dai, Fuduan Peng, Yunhe Liu, Akshaya Jadhav, Wenhua Lang, Claudio A. Arrechedera, Leticia Campos Clemente, Edwin R. Parra, Hsinyi Lu, Cara L. Haymaker, Ignacio I. Wistuba, Andrew Futreal, Andrea Viale, Michael J. Soth, Philip Jones, Joseph R. Marszalek, Timothy Heffernan, Giulio F. Draetta, Nizar M. Tannir, Jianjun Gao, Linghua Wang, Giannicola Genovese, Pavlos Msaouel. "Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence." Nature Communications, 2025. doi:10.1038/s41467-025-65462-z